Inhaled insulin: gone with the wind?

Mathieu, Chantal; Gale, E.A.M.

doi:10.1007/s00125-007-0875-x

Cited by 13 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although an inhalation formulation, Exubera ® , recieved FDA approval for human use, it was withdrawn recently because patient compliance and safety concerns were major problems [86].…”

Section: Biocompatibilitymentioning

confidence: 99%

Challenges and advances in nanoparticle-based oral insulin delivery

Rekha¹,

Sharma²

2009

Expert Review of Medical Devices

View full text Add to dashboard Cite

For many decades, rigorous efforts have been made worldwide to develop a successful oral insulin-delivery system, which still remains an elusive goal. However, over the past few years, tremendous understanding has evolved in the development of biocompatible and biodegradable polymers, synthesis of nanopeptide delivery systems, biocompatibility and its cellular uptake mechanisms. With these advancements, efforts are being directed toward nanoparticle-based oral peptide-delivery systems. It is established that nanoparticles enhance oral bioavailability by facilitating insulin uptake via a transcellular or paracellular pathway. In this process, the particle also reaches the systemic circulation. Hence, biocompatibility and the half-life of the particles in the systemic circulation is an important aspect that needs to be looked into. In this review, the various approaches adopted for nanoparticle-based oral insulin delivery, uptake mechanisms, biocompatibility and bioavailability of the nanoparticle are discussed.

show abstract

“…Although an inhalation formulation, Exubera ® , recieved FDA approval for human use, it was withdrawn recently because patient compliance and safety concerns were major problems [86].…”

Section: Biocompatibilitymentioning

confidence: 99%

Challenges and advances in nanoparticle-based oral insulin delivery

Rekha¹,

Sharma²

2009

Expert Review of Medical Devices

View full text Add to dashboard Cite

show abstract

“…A single case had been reported in comparatortreated patients, and all cases had a history of prior cigarette smoking [26]. The company stated that this sixfold increase in risk (0.13/1,000 cases vs 0.02) did not prove a causal connection, but the observation may have helped to motivate the precipitate removal of Exubera from the market on 17th October 2007 [27]. The effects of massive local concentrations of insulin in the lung cannot, however, be extrapolated to the safety or otherwise of subcutaneous insulin.…”

Section: Insulin Analogues and Cancermentioning

confidence: 99%

Does diabetes therapy influence the risk of cancer?

2009

Self Cite

View full text Add to dashboard Cite

“…So far, oral-administration of insulin has not been approved by FDA, and Exubera, FDAapproved inhalation formulated insulin through pulmonary route, was withdrawn in 2007 due to poor sales, shorter effective duration, and safety concern [52] . Nanodelivery of ARI's may provide a focused delivery to target tissues.…”

Section: Resultsmentioning

confidence: 99%

Aldose Reductase Inhibitors and Nanodelivery of Diabetic Therapeutics

Prior

Thapa

Hua

2012

MRMC

View full text Add to dashboard Cite

Nanotechnology is a rapidly emerging drug-delivery system that makes possible the controlled release of small molecules, and nanodelivery of therapeutic molecules using nanoparticles or nanogels represents a major improvement for more focused delivery of such therapeutic molecules. The delivery of insulin for the control of diabetes mellitus (DM) and aldose reductase inhibitor (ARI) for diabetic complications may provide better treatment of diabetes. A structural overview of aldose reductase including computational docking experiments with HAR-1, various ARIs, aldose-keto reductase, and nanodelivery of insulin, ARI's, and drug molecules are described.

show abstract

Inhaled insulin: gone with the wind?

Cited by 13 publications

References 14 publications

Challenges and advances in nanoparticle-based oral insulin delivery

Challenges and advances in nanoparticle-based oral insulin delivery

Does diabetes therapy influence the risk of cancer?

Aldose Reductase Inhibitors and Nanodelivery of Diabetic Therapeutics

Contact Info

Product

Resources

About